Integrated 18F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology by Fischer, Michael et al.
ORIGINAL ARTICLE
Integrated 18F-FDG PET/perfusion CT for the monitoring
of neoadjuvant chemoradiotherapy in rectal carcinoma:
correlation with histopathology
Michael A. Fischer & Bart Vrugt & Hatem Alkadhi &
Dieter Hahnloser & Thomas F. Hany &
Patrick Veit-Haibach
Received: 1 November 2013 /Accepted: 4 March 2014 /Published online: 24 April 2014
# Springer-Verlag Berlin Heidelberg 2014
Abstract
Purpose The aim of this study was to prospectively monitor
changes in the flow-metabolic phenotype (ΔFMP) of rectal
carcinoma (RC) after neoadjuvant chemoradiotherapy (CRT)
and to evaluate whether ΔFMP of RC correlate with histo-
pathological prognostic factors including response to CRT.
Methods Sixteen patients with RC (12 men, mean age 60.7±
12.8 years) underwent integrated 18F-fluorodeoxyglucose
(FDG) positron emission tomography (PET)/perfusion CT
(PET/PCT), followed by neoadjuvant CRT and surgery. In
13 patients, PET/PCT was repeated after CRT. Perfusion
[blood flow (BF), blood volume (BV), mean transit time
(MTT)] and metabolic [maximum and mean standardized
uptake values (SUVmax, SUVmean)] parameters as well as the
FMP (BF × SUVmax) were determined before and after CRT
by two independent readers and correlated to histopathologi-
cal prognostic factors of RC (microvessel density, necrosis
index, regression index, vascular invasion) derived from
resected specimens. The diagnostic performance of ΔFMP
for prediction of treatment response was determined.
Results FMP significantly decreased after CRT (p<0.001),
exploiting higher changes after CRT as compared to changes
of perfusion and metabolic parameters alone. Before CRT, no
significant correlations were found between integrated PET/
PCTand any of the histopathological parameters (all p>0.05).
After CRT, BV and SUVmax correlated positively with the
necrosis index (r=0.67/0.70), SUVmax with the invasion of
blood vessels (r=0.62) and ΔFMP with the regression index
(r=0.88; all p<0.05). ΔFMP showed high accuracy for pre-
diction of histopathological response to CRT (AUC 0.955,
95 % confidence interval 0.833–1.000, p<0.01) using a cut-
off value of −75 %.
Conclusion In RC, ΔFMP derived from integrated 18F-FDG
PET/PCT is useful for monitoring the effects of neoadjuvant
CRTand allows prediction of histopathological response to CRT.
Keywords Positron emission tomography and computed
tomography . Perfusion imaging . Colorectal neoplasms .
Neoadjuvant therapy . Biological markers
Introduction
Colorectal cancer (CRC) is the third most common malignan-
cy in men and women and is generally associated with high
mortality in the Western population [1, 2]. The introduction of
preoperative chemoradiotherapy (CRT) in the surgical man-
agement of patients with locally advanced stages (II/III) of
rectal carcinoma (RC) has significantly increased the 5-year
disease-free survival [3, 4]. However, treatment response to
CRT varies considerably between patients. Although 5-
fluorouracil (5-FU)-based CRT induces downstaging in ap-
proximately 49–70 % [5], a complete histopathological re-
sponse is achieved in only 8–14 % of the patients with
development of metachronous metastases in approximately
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30 % of cases [6, 7]. Depending on the degree of response,
treatment can be individually optimized by dose escalation or by
switching to more effective chemotherapeutic agents [8, 9].
Moreover, a substantial number of patients demonstrate an
inadequate response despite optimal treatment (non-
responders), resulting in unnecessary treatment toxicity as well
as delay in surgical intervention. Therefore, it is of major clinical
interest to accurately identify treatment response and to predict
outcome following preoperative CRT for patients with RC.
In routine clinical practice, computed tomography (CT)
plays an important role in the management of RC due to its
widespread availability, affordability and reproducibility.
However, due to its limited ability to discriminate residual
tumour from normal tissue in the bowel wall, CT alone is
partly insufficient for an accurate assessment of the response
to neoadjuvant CRT [10, 11]. Integration of functional data to
CT in terms of positron emission tomography (PET) with
[18F]fluoro-2-deoxy-D-glucose (FDG) allows one to quantify
increased glucose metabolism in cancer cells, improving as-
sessment of treatment response and enabling prediction of
patient survival [12]. Recently, perfusion computed tomogra-
phy (PCT) has emerged as a novel functional imaging tech-
nique and a promising new surrogate biomarker of angiogen-
esis [13–15], which is considered to play a pivotal role in
colorectal tumour growth and dissemination [16].
PCT-derived vascular parameters [blood flow (BF), blood
volume (BV), mean transit time (MTT)] are increasingly
applied for diagnosis, staging and outcome prediction of RC
[15, 17]. In addition, recently published data underline the
potential of PCT for assessment of treatment response to CRT
[18–20]. However, it remains unclear whether PET/CT-
derived parameters of glucose metabolism [maximum and
mean standardized uptake values (SUVmax, SUVmean)] exploit
surrogates similar to PCT parameters [21] or whether the two
methods are different surrogate biomarkers [22, 23]. If the
latter holds true, a combined assessment of the flow-metabolic
phenotype (FMP) of RC using integrated 18F-FDG PET/PCT
[24] might be of additional value in assessment of therapy
response as well as risk stratification of patients with CRC
receiving neoadjuvant therapy. Therefore, the aim of this
study was to prospectively monitor changes to the FMP of
RC after neoadjuvant CRT and to evaluate whether the FMP
of RC can predict response to CRT and patient survival.
Materials and methods
Patients
This prospective study was approved by the local Ethics
Committee and written informed consent was obtained from
all patients. Between July 2007 and August 2010 a total of 16
patients (12 men and 4 women, mean age 60.7±12.8 years,
range 31–78 years) undergoing 18F-FDG PET/CT imaging
prior to neoadjuvant CRT and surgery of locally advanced
RCwere included in this study. Inclusion criteria were biopsy-
proven rectal adenocarcinoma, locally advanced disease (T2–
4) with or without nodal involvement (N0, N1 or N2) or
metastases (M0/M1) after primary staging including clinical
examination, endorectal ultrasound and 18F-FDG PET/CT as
well as neoadjuvant treatment consisting of long-course CRT
followed by surgical resection of the tumour. Patients with
stage T1 rectal cancer, palliative disease and general contra-
indications to 18F-FDG PET (uncontrolled diabetes) or
contrast-enhanced CT (pregnancy, previous hypersensitivity
reaction to intravenous contrast agent, renal impairment, de-
fined as serum creatinine greater than 120 μmol/l or estimated
glomerular filtration rate less than 60 ml/min) were excluded.
All patients underwent integrated 18F-FDG PET including
PCT imaging before CRT. After neoadjuvant CRT, 13/16
(81 %) patients (10 men and 3 women, mean age 60.1±
11.1 years, range 31–78 years) underwent an additional
follow-up 18F-FDG PET/PCT scan.
Treatment
All patients received the same neoadjuvant CRT regimen.
Radiotherapy consisted of 45 Gy delivered over a period of
5 weeks and was combined with two courses of chemotherapy
consisting of 350 mg of fluorouracil per square metre of body
surface area per day and 20 mg leucovorin per square metre per
day, both given over a period of 5 days. Surgical resection was
performed 6–8 weeks after completion of CRT in all patients.
Histopathological assessment
Histopathological evaluation was performed by one patholo-
gist (B.V.; with 7 years of experience in pathology) who was
blinded to the results from PCT and PET analysis. Tissue
blocks were constructed according to the total mesorectal
excision (TME) protocol [25] and semi-thin 3-um sections
cut for routine examination. Pathological staging was per-
formed according to the recent TNM classification (7th edi-
tion, 2010) [26]. In addition, the following histopathological
prognostic markers were investigated: microscopic vascular
invasion (MVI), necrosis index (NI), microvessel density
(MVD) and tumour regression grade (TRG). Vascular and
lymphangio-invasion were assessed microscopically on a
two-point scale (present or absent) using additional histo-
chemical (elastin van Gieson) and immunohistochemical
stainings (D2-40, 1:50, Dako A/S, Glostrup, Denmark), re-
spectively. NI was assessed semiquantitatively [0=absent, 1=
focal (≤10 % of the tumour area), 2=moderate (10–30 %), 3=
extensive (≥30 %)] as described by Pollheimer et al. [27].
MVD (expressed as number of vessels per mm2) of the entire
tumour cross section was determined by immunohistochemistry
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with a CD34 antibody (QBEnd10, 1:400, Dako A/S, Glostrup,
Denmark) as previously described [14]. Briefly CD34-stained
slides were scanned, digitized and displayed on a high-
resolution colour monitor; ten microscopic fields (0.1817 mm2
each) within tumour tissue, each separated by five field widths,
were randomly chosen on each tumour-containing tissue block.
The number of vessels stained positive for CD34was counted at
a magnification factor of 400. The mean value of MVD was
calculated for the entire tumour cross section (hereafter termed
tumour cross section MVD). Assessment of the histological
response to CRT was achieved for each RC using the tumour
regression according to Dworak et al. [28]. This score identifies
five TRG based on the presence of residual tumour and the
extent of fibrosis: TRG 0, no regression; TRG 1, predominance
of vital tumour cells over peritumoural fibrosis (focal regres-
sion); TRG 2, predominance of fibrosis over vital tumour cells
(partial regression); TRG 3, residual tumour cells in fibrotic
tissue (subtotal regression); TRG 4, no vital tumour cells de-
tectable (total regression). Based on the Dworak classification,
tumours with TRG 0–1 scores were regarded as non-responders
and those with TRG 2–4 scores as responders.
Integrated 18F-FDG PET/PCT imaging
All patients were examined in the supine position on a com-
bined PET/CT in-line system (Discovery VCT, GEHealthcare,
Milwaukee, WI, USA). These dedicated systems integrate a full-
ring PET with a multislice helical 64-slice CT and permit the
acquisition of coregistered CT and PET images in one imaging
procedure. The patients were instructed to fast for 4 h prior to the
examination. Scanning was started 60 min after the i.v. injection
of a standard dose of 300–340 MBq FDG. Blood sugar levels
were checked prior to the injection of the FDG.
After the acquisition of a low-dose, non-enhanced CT
examination (80 mA, 140 kV, 0.5-s tube rotation, 4.25-mm
section thickness), which was used for attenuation correction
of the PET data as well as for the determination of anatomic
distribution of increased radionuclide uptake, the PET emis-
sion examination was acquired with an acquisition time of
2 min per bed position [15-cm axial field of view (FOV)/bed
position]. All PET images were reconstructed by using a
standard fully 3-D iterative algorithm (ordered subset expec-
tation maximization: 28 subsets, 2 iterations, 128×128 recon
matrix and overlap of 9 slices).
The PCTexamination was fully integrated into the standard
contrast-enhanced PET/CT procedure [29]. The FOV of the
PCTexamination was defined on the basis of the focal glucose
metabolismwithin the rectal wall with concomitant rectal wall
thickening by one experienced radiologist, who directly
reviewed the previously acquired PET/CT images on the
scanner console. After target lesion definition, intravenous
contrast injection was started by injecting a total dose of
70 ml contrast media (Ultravist 370, Bayer Schering Pharma,
Berlin, Germany) at a flow rate of 6 ml/s via a cubital vein.
Dynamic CT image acquisition for perfusion imaging was
started after a 5-s delay for 50 s in the area of interest using the
following imaging parameters: 1-s rotation time with 1 image/
s, cine duration 50 s, 8 slices, 5 mm slice thickness, 80 mA,
80 kV and effective radiation dose of 6 mSv. Thus, a
craniocaudal coverage of 4 cm was achieved for the perfusion
examination of the target RC lesion. The first contrast media
bolus was followed by a saline flush (20 ml, 5 ml/s). Since the
system did not allow for a shuttle mode at the time of the study,
a 4-cm FOV for perfusion imaging represents the maximum
coverage possible with the chosen time resolution. All images
were transferred to a commercially available workstation (Ad-
vantage Workstation 4.4, GE Healthcare, Milwaukee, WI,
USA) for further image post-processing (coregistration of
PET and non-enhanced CT images) and image analysis.
Image analysis
Figure 1 gives an overview of image series derived from
integrated PET/PCT and corresponding image analysis.
PET/CT data evaluation
PET data were evaluated by one board-certified radiologist and
one board-certified nuclear medicine physician/radiologist in
consensus according to routine clinical practice using dedicated
PET/CT software (Volume Viewer PET/CT, Advantage Work-
station 4.4, GE Healthcare), which provides multiplanar
reformatted images of PET alone, CT alone and fused PET/CT.
For quantitative analysis a cubic volume of interest (VOI) was
placed over the primary target RC lesion on the fused PET/CT
images by one of the two investigators. Using a threshold of
42%ofmaximumvoxel (default by software), the cuboidVOI is
automatically transformed into a threshold delimited VOI and
dedicated SUVmax and SUVmean based on the FDG uptake were
calculated separately for pretreatment (pre-SUVmax, pre-
SUVmean) and post-treatment (post-SUVmax, post-SUVmean). Fi-
nally, the percentage difference from pre- to post-treatment
values was calculated for both parameters (ΔSUVmax,
ΔSUVmean) as follows: (pre-SUV − post-SUV)/pre-SUV × 100.
PCT evaluation
All PCT data were evaluated using a commercially available
perfusion software (CT Perfusion 3.0, GE Healthcare, Milwau-
kee,WI, USA). A threshold of −5 to 120HUwas defined for soft
tissue visualization. The arterial input was defined by a circular
automated region of interest (ROI) in one of the internal iliac
arteries. The calculated time-enhancement curve and the paramet-
ric imaging maps for BF (ml/100 mg tissue per min), BV (ml/
100 mg tissue) andMTT (s) were automatically calculated by the
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software. The permeability surface (PS) was not calculated due to
the short acquisition time of the study protocol.
Two readers M.A.F. and P.V-H. with 5 and 8 years of
experience in abdominal radiology drew a freehand ROI de-
fined by the margin of the target RC lesion in every affected
slice of the perfusion volume (max. 8 slices) on one selected
contrast-enhanced image series of the arterial phase which best
delineated the tumour. Afterwards the ROIs were copied and
pasted to the coregistered colour-coded image maps and perfu-
sion parameters were recorded for the pre- (pre-BF, pre-BV,
pre-MTT) and post- (post-BF, post-BV, post-MTT) treatment
examinations separately. Similar to PET analysis (see above),
percentage differences from pre- to post-treatment values were
calculated for each parameter (ΔBF, ΔBV, ΔMTT). Finally,
the FMP in terms of the flow-metabolic product (BF ×
SUVmax) was calculated for each examination [pre-(BF ×
SUVmax), post-(BF × SUVmax)], and the percentage difference
after CRT [Δ(BF × SUVmax)] was determined. The product
was chosen over the ratio of both parameters [24] asΔBF and
ΔSUVmax showed a positive correlation, which was stronger as
compared to ΔBF and ΔSUVmean (see “Results” section).
Statistical analysis
Data were descriptively reviewed and variables are expressed
as mean ± SD or as frequencies and percentages. The inter-
observer variability of perfusion parameters (BF, BV, MTT)
was assessed using Lin’s concordance correlation coefficient
(ρc) with 95 % confidence interval (CI) [30]. Because inter-
observer variability was minimal (see “Results” section), the
mean of both measurements was taken for further analysis.
Correlation between PCT and/or PET values as well as MVD
was assessed using Pearson’s correlation coefficient (r),
whereas correlation of PCT and/or PET values with NI or
regression index was assessed with Spearman’s rank correla-
tion coefficient (ρ).
Student’s t test for related samples was used to test for
significant differences between pre- and post-therapeutic
PCT and/or PET values. Differences of PCT and/or PET
values between different groups of histopathological tumour
regression were tested for statistical significance with the
Mann-Whitney U test. The log-rank test was used to deter-
mine significant differences of 3-year survival between re-
sponders (TRG≥2) and non-responders (TRG<2) to CRT.
To investigate the diagnostic accuracy ofΔ(BF × SUVmax)
for prediction of histopathological therapy response, the area
under the curve (AUC) was determined by receiver-operating
characteristic (ROC) analysis. The cut-off Δ(BF × SUVmax)
value was chosen to yield 100 % sensitivity for predicting
treatment response as defined by histopathology. Sensitivity,
specificity, negative predictive value (NPV) and positive pre-
dictive value (PPV) are given with Wilson CIs. A p value
<0.05 was considered statistically significant. All statistical
analyses were performed using commercially available soft-
ware (SPSS, release 17.0, Chicago, IL, USA).
Results
Patients
The median interval between the baseline PET/PCT scan and
surgery was 102±21 days (range 68–116). The 3-year overall
survival rate was 100 % in 11/16 (69 %) patients with a mean
Fig. 1 Combined assessment of tumour perfusion and metabolism with
integrated PET/PCT. A 57-year-old male patient with locally advanced RC
(T3, N0, M0) undergoing simultaneous 18F-FDG PET/CT (a–d) and PCT
(e–j) before (left side) and after (right side) neoadjuvant CRT. Pre- and post-
therapeutic SUVmax and SUVmean were calculated from
18F-FDG PET (a
vs b) and 18F-FDG PET/CT (b vs c), respectively, whereas BF (e vs f), BV
(g vs h) and MTT (i vs j) were calculated from ROI measurements (white
circle) on corresponding perfusionmaps (e–j). The relative change between
pre- and post-treatment SUVmax, SUVmean, BF, BV and MTT measure-
ments was −50.3, −47.4, −34.5, −21.4 and +33.2 %, respectively. Histo-
pathological analysis revealed moderate tumour regression (TRG 2), focal
tumour necrosis (NI of 1) and intermediate MVD
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follow-up period of 950±213 days (range 553–1092). Of 16
patients, 3 (31%) died within a 3-year period (median survival
287±350 days, range 37–866). Three of five (60 %) patients
died from reasons unrelated to RC including perioperative
complications (n=2) and alcohol-related liver failure (n=1).
These patients were excluded from the disease-specific sur-
vival analysis. Two of five (40 %) patients died because of
progressive disease. In the group of the 13 patients with a
follow-up PET/PCT examination after CRT, the median inter-
val between the baseline and the follow-up PET/PCTscanwas
89±15 days (range 58–104), between completion of CRT and
the follow-up scan 41±9 days (range 35–56) and between the
follow-up PET/PCT scan and surgery 8±5 days (range 1–21).
Histopathological findings
The pathological TNM classification included the following
stages: ypT1 N0 (n=2), ypT2 N0 M0 (n=2), ypT2 N1 M0
(n=1), ypT3 N0M0 (n=7), ypT3 N1M1 (n=1), ypT3 N2M0
(n=2) and ypT4 N2 M1 (n=1). Microvascular invasion was
present in 4/16 (25 %) patients, whereas lymphangio-invasion
was detected in 1/16 (6%) patients. The meanMVDwas 76.6
±14.4 (range 56–107). No necrosis was observed in 7/16
(43.8 %), focal necrosis in 4/16 (25 %), moderate necrosis in
3/16 (18.8 %) and extensive necrosis in 2/16 (12.5 %) pa-
tients. Tumour regression according to the Dworak classifica-
tion revealed a TRG 1 in 2/16 (12.5 %), a TRG 2 in 10/16
(62.5 %), a TRG 3 in 2/16 (12.5 %) and a TRG 4 in 2/16
(12.5 %) patients. An inadequate histological response to CRT
(TRG 1) was observed in 2/16 (12.5 %) patients, who were
classified as non-responders. All other patients (87.5 %) dem-
onstrated a subtotal to total regression following CRT and
therefore were regarded as responders.
Integrated PET/PCT
Interreader agreement (IRA) of perfusion parameters
IRA was good for pre-BF [ρc=0.82, 95 % confidence limit
(CL) 0.56–0.93], pre-BV (ρc=0.86, 95% CL 0.67–0.95), pre-
MTT (ρc=0.90, 95 % CL 0.77–0.96), post-BV (ρc=0.89,
95 % CL 0.69–0.97), post-MTT (ρc=0.83, 95 % CL 0.56–
0.94) and ΔBF (ρc=0.90, 95 % CL 0.71–0.97) and excellent
for post-BF (ρc=0.92, 95 % CL 0.79–0.97) and ΔBV (ρc=
0.93, 95 % CL 0.79–0.98). Moderate IRA was seen for
ΔMTT (ρc=0.73, 95 % CL 0.34–0.90).
Monitoring of neoadjuvant CRT
Table 1 and Fig. 2 give an overview of pre- and post-
therapeutic perfusion and metabolic parameters and the
flow-metabolic product with corresponding percentage
changes and p values after neoadjuvant CRT. The greatest
post-therapeutic change was revealed for Δ(BF × SUVmax).
Correlation of PET and PCT parameters
No significant correlation was found between any combina-
tion of perfusion and metabolic parameters between pretreat-
ment, post-treatment and Δ values.
Correlation of PET and/or PCT with histopathology
For pretreatment PET and/or PCT parameters, no significant
correlation was found with any of the histopathological prog-
nostic markers. After treatment all PET and PCT parameters
except for post-MTT correlated significantly with the NI. In
addition, a significant correlation was found between post-
SUVmax, post-SUVmean, post-FMP and TRG as well as be-
tween SUVmax and MVI of blood vessels (Table 2). No
significant correlation was seen for TNM and MVD (all
p>0.05).
Changes (%) of PET and/or PCT parameters from pre- to
post-therapy showed a significant inverse correlation for all
Δ values with TRG (all p<0.05) except for ΔMTT. The
ΔFMP (BF × SUVmax) exploited the highest correlation
coefficient (ρ=−877, p<0.001) of all parameters (Table 3).
Only ΔFMP (BF × SUVmax) showed a significant difference
between partial, incomplete and complete histopathological
regression with an AUC of 0.955 (95 % CI 0.833–1.000,
p=0.009), an AUC of 0.972 (95 % CI 0.809–1.000,
p=0.048) and an AUC of 1.0 (95 % CI 1.000–1.000,
p=0.03), respectively (Fig. 3).
Prediction of histopathological response to CRT
ΔPETand/orΔPCT parameters are shown in Table 3. Using a
cut-off ΔFMP (BF × SUVmax) of −75 %, we found a sensi-
tivity of 100 % (CI 75–100 %) and a specificity of 91 % (CI
69–100 %) for prediction of therapy response (Fig. 4). The
corresponding PPV was 67 % (CI 13–100 %) and NPV was
100 % (CI 95–100 %).
Discussion
In this prospective study we have shown that changes in
the FMP derived from integrated PET/PCT allows for
monitoring of neoadjuvant CRT, exploiting higher
changes after CRT as compared to changes of perfusion
and metabolic parameters alone. Before CRT, integrated
PET/PCT did not correlate with any of the investigated
histopathological parameters. After CRT, the strong as-
sociation of BV with NI, SUVmax with vascular inva-
sion and ΔFMP with tumour regression demonstrates
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that PET/PCT measurements reflect histopathological
changes indicative of a poor prognosis and as a result
are helpful in predicting the response to CRT and over-
all survival. Accordingly, ΔFMP showed an excellent
diagnostic accuracy for prediction of histopathological
response using a cut-off value of −75 %.
Accurate monitoring of neoadjuvant CRT is of major
clinical importance for an individually tailored treatment
regime of patients with RC [6–9, 31]. PET/CT is in-
creasingly used in routine clinical practice for assess-
ment of treatment response as metabolic parameters
(SUVmax, SUVmean) decrease in cases of tumour regres-
sion [12]. Recent studies showed the potential of PCT
for monitoring of CRT in RC, while decreases in per-
fusion parameters (BF, BV) are thought to reflect an-
giogenic changes in neoplastic tissue in terms of a
decreased number of arteriovenous shunts and a reduced
volume of the vascular bed [18–20]. Consistent with
these studies, our results demonstrate a significant de-
crease in perfusion parameters (BF, BV) over the course
of CRT. However, we observed no significant difference
in MTT, which is in partial agreement with the previ-
ously mentioned studies. This might be explained by
insubstantially different changes to the volume of distri-
bution (V) and the flow through the exchange unit (F)
in RC over the course of CRT (MTT=V/F) and might
be dependent on the time point of the follow-up exam-
ination as volume changes usually appear more slowly
than flow-related differences [32]. Compared with met-
abolic parameters derived from 18F-FDG PET, PCT
parameters in terms of ΔBF and ΔBV showed a similar
potential for monitoring of CRT. However, combination
of both parameters to a flow-metabolic product showed
the highest changes after CRT (−81 %) as compared to
changes of perfusion and metabolic parameters alone,
indica t ing a potent ia l benef i t f rom combined
multimodality assessment of perfusion and metabolic
parameters for monitoring of neoadjuvant CRT.
Several studies have investigated the relationship be-
tween 18F-FDG PET and PCT [22–24, 29, 33, 34],
demonstrating that the balance between tumour vascu-
larity and glucose metabolism offers substantial infor-
mation concerning tumour adaption to the microenviron-
ment. Matched high glucose metabolism with increased
vascularity (coupling) represents a different biological
status compared with mismatch of high metabolism
and lower vascularity, the latter possibly indicating ad-
aptation to hypoxia [35]. Accordingly, combined assess-
ment of tumour BF and metabolism in terms of FMP
was shown to provide additional diagnostic information
for prediction of treatment response in breast and pan-
creatic cancer [36–38]. In CRC, low flow and high
metabolism were associated with higher levels of
hypoxia-inducible factor 1α (hypoxia) and vascular en-
dothelial growth factor (angiogenesis); however,
uncoupling of flow and metabolism was revealed exclu-
sively in stage I/II CRC, whereas coupling was demon-
strated for stage III/IV CRC [23, 24]. Our results par-
tially underline these findings as no coupling was re-
vealed between 18F-FDG PET and PCT before and after
CRT for the included stage II/III RC. Accordingly, the
Table 1 Changes of 18F-FDG PET, PCT and combined parameters (FMP) during neoadjuvant CRT
Monitoring of CRT Before CRT (n=17) After CRT (n=13) Difference (% ) p valuea
PCT
BF (ml/100 mg/min) 68.1±24.0 32.8±16.2 −47.3±25.2 <0.001
BV (ml/100 mg) 6.5±2.4 3.6±1.7 −41.1±25.4 =0.001
MTT (s) 9.8±2.4 12.1±3.1 23.8±34.1 0.089
18F-FDG PET
SUVmax 17.5±7.1 4.6±2.3 −68.1±22.9 <0.001
SUVmean 6.8±2.1 2.9±0.8 −52.8±21.4 <0.001
FMP
BF × SUVmax (ml/100 mg/min) 1,172.7±690.3 144.0±114.9 −81.0±23.0 <0.001
BF blood flow, BV blood volume, MTT mean transit time
a Student’s t test for related samples was used to test for significant differences between pre- and post-therapeutic values. Italics indicate a non-significant result
Fig. 2 Comparison of pre- and post-CRT measurements of a PCT-
derived vascular parameters (BF, BV, MTT), b 18F-FDG PET-derived
glucose metabolism parameters (SUVmax, SUVmean) and c combined
parameters (FMP). Data are displayed as box-and-whisker plots. Line
within box indicates median, boundary of boxes indicates 25th and 75th
percentiles and error bars indicate smallest and largest values within 1.5
box lengths of 25th and 75th percentiles
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flow-metabolic relationships of other tumour entities like
non-small cell lung cancer [34], breast cancer [39] and
head and neck squamous cell cancer [22, 40, 41] were
shown to depend upon tumour size and stage, indicating
that BF and glucose uptake represent independent mea-
sures of tumour biology.
However, no correlation was found for pretreatment
perfusion and metabolic parameters alone and in com-
bination (flow-metabolic ratio or product) with prog-
nostic histopathological parameters evaluated in this
study. This might be explained by the time point of
histopathological evaluation which was, defined by
standard routine clinical practice, performed after sur-
gery and thus after CRT. Therefore, our results indicate
that integrated PET/PCT at baseline might be of limit-
ed value for prediction of tumour grade and treatment
response to neoadjuvant CRT in patients with locally
advanced RC. This is consistent with a study evaluat-
ing the prognostic value of metabolic parameters [42]
but in contrast to results of two recent studies reveal-
ing the prognostic value of baseline perfusion parame-
ters for prediction of treatment response to neoadjuvant
CRT [19, 20]. However, both studies defined treatment
response (local downstaging after CRT/TRG 3–4) dif-
ferently compared to our study (TRG 2–4).
In contrast to pretreatment parameters, a significant
positive correlation of several PCT and 18F-FDG PET
parameters with histopathological factors was revealed
after CRT. Of those, post-BV/post-SUVmax and post-
SUVmax showed the highest correlation with the NI
and the invasion of blood vessels. The presence of
tumour necrosis has been related to intra-/peritumoural
inflammation and microsatellite status [43] and was
shown to be an independent predictor of disease pro-
gression and cancer-specific survival [27]. Similar to
microvascular invasion of blood or lymphogenic vessels,
it is therefore regarded as a surrogate for a more ag-
gressive tumour phenotype. Thus, the low BV might be
explained by a lower amount of viable tumour tissue of
necrotic versus non-necrot ic tumours, whereas
dedifferentiated (more aggressive) carcinomas typically
show a constitutively upregulated glycolysis [44], which
explains the higher SUVmax of necrotic and invasive RC
demonstrated in our study.
Similar to previous studies, we did not find a rela-
tionship between perfusion or metabolic parameters and
the MVD [14, 45, 46], which is considered a surrogate
marker of tumoural angiogenesis and was correlated
with poor outcome in RC [47]. However, another study
suggests a relationship between MVD and RC [13],
indicating that different results might be due to under-
estimation of the MVD with CD34 antibodies [48] or to
the high interobserver and methodological variability of
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MVD assessment [23, 49]. Moreover, we did not ana-
tomically match histopathological samples and perfusion
measurements, which implies a potential measurement
bias, although the whole tumour volume was assessed
using integrated PET/PCT.
The histopathological TRG is a known prognostic
factor in locally advanced RC treated with neoadjuvant
CRT and the use of the standardized Dworak grading
system to evaluate the TRG in RC was shown to be
reliable to identify patients with a worse prognosis [50,
51]. In our study, correlation of Dworak’s TRG derived
from histopathology and PCT/18F-FDG PET parameters
was demonstrated for metabolic changes (ΔSUVmax/
mean) and TRG 2, whereas changes to tumour perfusion
(ΔBF/BV) showed significant correlation with TRG 3
and 4. Accordingly, changes to tumour metabolism
seem to appear earlier (lower threshold) in treated RC
(demonstrating a possibly higher sensitivity), whereas
changes to tumour perfusion seem to appear later in
the presence of subtotal or total tumour fibrosis, thus
demonstrating a possibly higher specificity. As changes
to perfusion were shown to be linked to chemothera-
peutic agents like bevacizumab, whereas metabolic
changes occurred predominantly after addition of
Table 2 Correlation of post-CRT 18F-FDG PET, PCTand combined parameters (FMP) with histopathological prognostic factors derived from resected
specimens
Correlation TRG NI MVI MVD TNM
BVS LVS T N
PCT
Post-BF (ml/100 mg/min) −0.552 0.597 0 0.386 −0.057 −0.328 0.047
Post-BV (ml/100 mg) −0.486 0.668 0.125 0.311 0.114 −0.202 0.032
Post-MTT (s) 0.240 −0.132 −0.178 0.309 0.196 0.088 0.111
18F-FDG PET
Post-SUVmax −0.795 0.699 0.624 0.309 0.230 0.243 0.079
Post-SUVmean −0.676 0.565 0.472 0.077 0.248 0.25 −0.223
FMP
Post-BF × Post-SUVmax (ml/100 mg/min) −0.795 0.734 0.401 0.463 0.113 −0.003 −0.063
Spearman’s rank correlation coefficients (ρ) are displayed for all correlations except for MVD (Pearson’s r). Boldface indicates significant correlation
(p<0.05)
TRG tumour regression grade, NI necrosis index,MVI microscopic vascular invasion, BVS blood vessels, LVS lymphogenic vessels,MVD microvessel
density, T tumour, N node, BF blood flow, BV blood volume, MTT mean transit time, Post- post-CRT
Table 3 Comparison of changes (Δ) to 18F-FDG PET, PCT and combined parameters (FMP) over the course of CRT with TRG derived from
histopathological analysis
Response to CRT TRG
Correlation (ρ) TRG≥2 (p value) TRG≥3 (p value) TRG=4 (p value)
PCT
ΔBF (%) −0.795 >0.05 <0.05 <0.05
ΔBV (%) −0.699 >0.05 <0.05 <0.05
ΔMTT (%) 0.513 >0.05 <0.05 >0.05
18F-FDG PET
ΔSUVmax (%) −0.666 <0.05 >0.05 >0.05
ΔSUVmean (%) −0.723 <0.05 <0.05 >0.05
FMP
Δ(BF × SUVmax) (%) −0.877 <0.05 <0.01 <0.05
Spearman’s rank correlation coefficient (ρ). Boldface indicates significant correlation (p<0.05) or significant differences between different regression
groups. Δ− indicates percentage difference between pre- and post-CRT values
TRG ranked 0–4. TRG 2 partial regression, TRG 3 incomplete regression, TRG 4 complete regression, BF blood flow, BV blood volume, MTT mean
transit time
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radiation therapy in RC [35], our results confirm that
both parameters exploit different surrogate markers for
therapy response and suggest the benefit of combined
assessment of perfusion and metabolism in terms of a
flow-metabolic product (coupling of ΔBF and
ΔSUVmax). ΔFMP was the only parameter to show a
significant difference between all groups of TRG pres-
ent in our study. Similar to the previously mentioned
study of Dhadda et al. [50], we defined specimens with
a TRG of 2–4 as responders and specimens with a
TRG of 0–1 as non-responders to CRT as both groups
showed a significant difference in patient survival. By
doing so, ΔFMP showed an excellent accuracy for
prediction of treatment response to neoadjuvant CRT
in patients with RC.
Limitations
We have to acknowledge the small patient population as a
limitation, and further studies on larger groups of patients are
required to confirm our findings. However, our study indicates
that PET/PCT may serve as an important adjunct in determin-
ing the biological response to CRT and in predicting histo-
pathological and clinical outcome in patients with RC. Sec-
ondly, perfusion imaging contributes a substantial increase of
radiation dose to the patient. However, evaluated tumour
volumes (4 cm) and therefore applied radiation doses were
relatively small and all patients underwent neoadjuvant radio-
therapy, which is associated with significantly higher radiation
exposure. Moreover, additional parameters of integrated PET/
PCT such as the PS area product or the total lesion glycolysis
and PETvol need to be evaluated in future. Finally, the accu-
racy of perfusion measurements have been shown to depend
on technical and individual aspects like temporal scan interval
[52], post-processing software [53], tumour ROI placement
and observer variation [54], which hamper a comparison of
PCT measurements between different vendors. Howev-
er, ΔFMP should be robust enough to remain unaffect-
ed by those confounding factors if baseline and preop-
erative examinations are performed by the same inves-
tigator and imaging system.
Conclusion
The ΔFMP of RC derived from integrated 18F-FDG PET/
PCT has potential for monitoring the effects of neoadjuvant
CRT and allows prediction of histopathological response to
CRT.
Conflicts of interest None.
Fig. 3 Comparison of percentage changes (Δ) to BF, SUVmax and the
combination of both parameters in terms of FMP (BF × SUVmax) over the
course of CRT in regards to the TRG as derived from histopathological
analysis of the resected specimens. Significant inverse correlation was
shown for all Δ values with TRG (all p<0.05). However, Δ(BF ×
SUVmax) exploited the highest correlation coefficient (ρ=−877,
p<0.001) and was the only parameter that showed a significant difference
between partial, incomplete and complete histopathological regression
(p<0.05). Data are displayed as box-and-whisker plots. Line within box
indicates median, boundary of boxes indicates 25th and 75th percentiles
and error bars indicate smallest and largest values within 1.5 box lengths
of 25th and 75th percentiles
Fig. 4 Diagnostic accuracy of pre- to post-therapeutic changes to the
FMP Δ(BF × SUVmax) for prediction of response to CRT as determined
by histopathology. ROC analysis revealed an AUC of 0.955 (95 % CI
0.833–1.000, p=0.009), a sensitivity of 100 % (CI 75–100 %) and a
specificity of 91 % (CI 69–100 %) using a cut-off value of −75 %.
The corresponding PPV was 67 % (CI 13–100 %) and NPV was 100 %
(CI 95–100 %)
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